[1] Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010[J]. The Lancet, 2013, 380(9859): 2144-2162. [2] Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis[J]. Science, 1992 ,256(5054):184-185. [3] Laeor PN, Buniel MC, Furlow PW. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease[J]. J Neurosci, 2007, 27(4): 796-807. [4] Doraiswamy PM, Krishnan KRR, Oxman T, et al. Does antidepressant therapy improve cognition in elderly depressed patients[J]?J Gerontol A Biol Sci Med Sci, 2003, 58(12): M1137-M1144. [5] Kim HJ, Kim W, Kong SY. Antidepressants for neuro-regeneration: from depression to Alzheimer's disease[J]. Arch Pharm Res, 2013, 36(11): 1279-1290. [6] Lee HB, Lyketsos CG. Depression in Alzheimer's disease: heterogeneity and related issues[J]. Biol Psychiatry, 2003, 54(3): 353-362. [7] Marlatt MW, Lucassen PJ, van Praag H. Comparison of neurogenic effects of fluoxetine, duloxetine and running in mice[J]. Brain Res, 2010, 1341: 93-99. [8] Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory[J]. Nat Protoc, 2006, 1(2): 848-858. [9] Byers AL, Yaffe K. Depression and risk of developing dementia[J]. Nat Rev Neurol, 2011, 7(6): 323-331. [10]Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia[J]. J Urol, 1992, 148(5): 1467-1474. [11]Liu X, Zhang J, Sun D, et al. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia[J]. Clin Interv Aging, 2014, 9: 411-418. [12]Trinchese F, Liu S, Battaglia F, et al. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice[J]. Ann Neurol, 2004, 55(6): 801-814. [13]Molteni R, Calabrese F, Bedogni F, et al. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions[J]. Int J Neuropsychopharmacol, 2006, 9(3): 307-317. [14]Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease[J]. Nat Med, 2009, 15(3): 331-337. [15]Lu B, Nagappan G, Guan X, et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases[J]. Nat Rev Neurosci, 2013, 14(6): 401-416. [16]Huang GJ, Ben-David E, Piella AT, et al. Neurogenomic evidence for a shared mechanism of the antidepressant effects of exercise and chronic fluoxetine in mice[J]. PloS One, 2012, 7(4): e35901. [17]An JJ, Gharami K, Liao GY, et al. Distinct role of long 3′ UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons[J]. Cell, 2008, 134(1): 175-187. |